文献速递皮肤肿瘤

原发灶不明黑色素瘤显示日光暴露相关致癌模式且临床病程与已知原发灶黑色素瘤相当

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.
PubMed 文献 · Br J Dermatol · 2026-01-01

本研究基于德国DeCOG ADOREG注册研究和埃森大学医院肿瘤数据库,纳入1999至2022年诊断的727例原发灶不明黑色素瘤(MUP)患者和587例III/IV期已知原发灶黑色素瘤(MKP)患者,中位随访3.5年。基因分析显示MUP以C>T和CC→TT突变为最常见核苷酸变异,中位肿瘤突变负荷为5个突变/Mb,支持其起源于日光暴露部位。校正年龄、性别和肿瘤分期后,MUP与MKP的总生存率相当,48个月总生存率分别为65%和68%。

要点

  • MUP的基因突变谱呈紫外线特征,提示原发灶可能位于日光暴露皮肤。
  • 校正年龄、性别和分期后,MUP与MKP的总生存率无显著差异。
  • MUP中BRAF V600E突变占39.1%,NRAS突变占33.6%,未检测到活化KIT突变。

核心结论

  • MUP的致癌模式显示紫外线突变特征,提示其起源于日光暴露部位。
  • MUP的总生存率与MKP相当。

研究设计与样本

  • 队列研究,纳入1999至2022年诊断的727例MUP患者和587例III/IV期MKP患者,中位随访3.5年。
  • MUP患者来自德国DeCOG ADOREG前瞻性多中心真实世界注册研究和埃森大学医院肿瘤数据库;MKP对照来自埃森皮肤癌中心连续患者。
  • 对可获得的肿瘤样本进行下一代测序基因分析。

主要发现

  • MUP患者首次诊断中位年龄62岁(IQR 53-73),MKP为63岁(IQR 52-75)。
  • MUP患者中男性448例(61.6%),MKP中男性330例(56.2%)。
  • 727例MUP患者中337例(46.4%)初诊时为III期。
  • 全部MUP患者48个月总生存率为65%(95%CI 61-69),全部MKP患者为68%(95%CI 64-72)。
  • 校正年龄、性别和肿瘤分期后,MUP与MKP的总生存率可比。

关键数值与推荐

  • 110例MUP肿瘤基因分析显示C>T和CC→TT突变是最常见核苷酸变异。
  • 中位肿瘤突变负荷为5个突变/Mb(95%CI 4-5)。
  • 活化BRAF V600E(c.620T>A)突变见于43例(39.1%),活化NRAS突变见于37例(33.6%),RAC1 P29S突变见于7例(6.3%),TERT启动子突变见于73例(66.4%)。
  • 未检测到活化KIT突变。

临床怎么用

  • MUP的基因突变谱和生存结局与日光暴露相关MKP相似,支持按黑色素瘤常规原则进行管理。
  • MUP中BRAF V600E和NRAS突变率较高,可参考MKP的分子检测策略指导靶向治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanoma of unknown primary (MUP) accounts for up to 10% of all cases of metastatic melanoma. The origin of MUP is unclear, and previous studies on the clinical course in comparison with cutaneous melanoma have reported varying results. OBJECTIVES: The study was conducted to assess the oncogenic pattern of MUP and to compare the clinical course with that of melanoma of known cutaneous primary (MKP). METHODS: Patients with MUP diagnosed between 1999 and 2022 were included in this cohort study from the prospective multicentre real-world DeCOG (German Dermatologic Cooperative Oncology Group) registry ADOREG and from the tumour database of the University Hospital Essen. For comparison, a cohort of consecutive patients with MKP with stage III or IV disease from the skin cancer centre Essen between 1999 and 2022 was used. The median follow-up was 3.5 years. Available tumour samples were genetically analysed using next-generation sequencing. Survival outcome adjusted for age, sex and tumour stage was compared between patients with MUP and those with MKP, using the Kaplan-Meier method. RESULTS: In total, 727 patients with MUP and 587 with MKP were identified. Median age at first diagnosis was 62 years [interquartile range (IQR) 53-73] for MUP and 63 years (IQR 52-75) for MKP. Most patients were male, 448 (61.6%) with MUP and 330 (56.2%) with MKP. Of the 727 patients with MUP, 337 (46.4%) had stage III disease at first diagnosis. Overall survival (OS) at 48 months was 65% [95% confidence interval (CI) 61-69] for all patients with MUP and 68% (95% CI 64-72) for all patients with MKP. Survival analyses adjusted for age, sex and tumour stage showed comparable OS rates for patients with MUP and MKP. Genetic analyses of tumours from 110 patients with MUP detected C>T and CC→TT mutations as the most common nucleotide variations. Median tumour mutational burden was 5 mutations per Mb (95% CI 4-5). Activating BRAF V600E (c.620T>A) mutations were detected in 43 patients (39.1%), activating NRAS mutations in 37 (33.6%), RAC1 P29S mutations in 7 (6.3%) and TERT promoter mutations in 73 (66.4%) of the analysed tumour samples. No activating KIT mutations were detected. CONCLUSIONS: The oncogenic pattern of MUP showed an ultraviolet mutation signature, suggesting an origin in sun-exposed areas. OS of MUP is comparable with that of MKP. Melanoma is an aggressive form of skin cancer. It can spread to other parts of the body and become life-threatening. In some cases, tests show melanoma has spread to other parts of the body, but the original (‘primary’) tumour site on the skin is undetected. This is called ‘melanoma of unknown primary’ (MUP). Overall, MUP accounts for up to 10% of all melanomas that have spread. This study was carried out by researchers at the University Hospital Essen, Germany. We wanted to learn how MUP compares with ‘melanoma originating from a known primary’ tumour site on the skin (MKP). We studied 727 patients with MUP and 587 with MKP. We analysed the gene sequences of tumour samples from these patients using a technique called ‘next-generation sequencing’. We found that the genetic patterns in MUP resembled those of melanomas originating from sun-exposed areas of the skin. We also found that the overall survival rates for patients with MUP were similar to those of patients with MKP. In conclusion, we detected that the genetic characteristics and survival rates of patients with MUP are similar to those of patients with MKP. This information helps doctors and patients better understand this type of cancer. Thus, we can ultimately make more informed decisions about treatment.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lodde G, Dollani J, Galetzka W, et al. Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma. Br J Dermatol. 2026. PMID: 41719057. doi:10.1093/bjd/ljaf499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。